Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AOMS1
MCID: ABD014
MIFTS: 62

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

About this section

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 57 12 15
Metabolic Syndrome X 57 12 73 29 54 70
Metabolic Syndrome 44 62 39 17
Abdominal Obesity Metabolic Syndrome 70
Dysmetabolic Syndrome X 12
Metabolic Disease 17
Aoms1 57

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:14221
OMIM® 57 605552
OMIM Phenotypic Series 57 PS605552
ICD9CM 34 277.7
MeSH 44 D024821
NCIt 50 C84442
SNOMED-CT 67 190394009
MedGen 41 C4552048
UMLS 70 C0524620 C2930930
Sources

Summaries for Abdominal Obesity-Metabolic Syndrome 1

About this section
OMIM® : 57 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552) (Updated 20-May-2021)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to fatty liver disease and acquired metabolic disease, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is TYR (Tyrosinase), and among its related pathways/superpathways are Glucose / Energy Metabolism and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Metyrapone and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and endothelial, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 62 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease. In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries. Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 73 Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal... more...

Sources

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

About this section

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3 Abdominal Obesity-Metabolic Syndrome 4

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1189)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 32.2 SERPINE1 PPARG MIR122 LEP INS ADIPOQ
2 acquired metabolic disease 32.2 SERPINE1 PPARG LEP INS GHRL ADIPOQ
3 prediabetes syndrome 31.9 SERPINE1 PPARG LEP INS GHRL ADIPOQ
4 abdominal obesity-metabolic syndrome quantitative trait locus 2 31.8 SERPINE1 PPARG LEP INS AOMS1 ADIPOQ
5 liver disease 31.8 MIR122 MEG3 LEP INS ADIPOQ
6 sleep apnea 31.5 SERPINE1 NOS3 LEP INS GHRL ADIPOQ
7 non-alcoholic steatohepatitis 31.5 SERPINE1 PPARG MIR122 INS GHRL ADIPOQ
8 arteries, anomalies of 31.5 SERPINE1 NOS3 MIR33A MIR122 LEP INS
9 chronic kidney disease 31.4 SERPINE1 PPARG NOS3 LEP INS GHRL
10 gestational diabetes 31.4 SLC2A1 PPARG LEP INS ADIPOQ
11 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.4 PPARG LEP INS ADIPOQ
12 hyperandrogenism 31.3 PPARG INS HSD11B1 ADIPOQ
13 lipoprotein quantitative trait locus 31.2 SERPINE1 PPARG NOS3 INS ADIPOQ
14 cerebrovascular disease 31.2 SERPINE1 MEG3 LEP INS ADIPOQ
15 leptin deficiency or dysfunction 31.2 PPARG LEP INS GHRL ADIPOQ
16 acanthosis nigricans 31.2 PPARG LEP INS ADIPOQ
17 end stage renal disease 31.2 NOS3 LEP INS ADIPOQ
18 kidney disease 31.1 SERPINE1 PPARG NOS3 NAGLU LEP INS
19 pre-eclampsia 31.1 SERPINE1 NOS3 LEP INS ADIPOQ
20 apnea, obstructive sleep 31.0 SERPINE1 NOS3 LEP INS GHRL ADIPOQ
21 arteriosclerosis 31.0 SERPINE1 PPARG NOS3 INS GHRL ADIPOQ
22 sleep disorder 31.0 LEP INS GHRL ADIPOQ
23 inherited metabolic disorder 31.0 PPARG MIR122 LEP INS ADIPOQ
24 myocardial infarction 31.0 SERPINE1 PPARG NOS3 LEP INS GHRL
25 anovulation 31.0 LEP INS GHRL
26 overnutrition 30.9 SERPINE1 PPARG MIR122 LEP INS GHRL
27 microvascular complications of diabetes 5 30.9 SERPINE1 NOS3 INS
28 liver cirrhosis 30.9 PPARG MIR122 MEG3 LEP INS ADIPOQ
29 amenorrhea 30.9 LEP INS GHRL
30 eating disorder 30.9 LEP GHRL ADIPOQ
31 hyperinsulinism 30.8 SERPINE1 PPARG LEP INS GHRL ADIPOQ
32 glucose intolerance 30.7 PPARG NOS3 LEP INS GHRL ADIPOQ
33 bone resorption disease 30.7 PPARG MIR122 LEP INS
34 osteoporosis 30.7 SERPINE1 PPARG NOS3 LEP INS HSD11B1
35 hyperthyroidism 30.6 LEP INS GHRL
36 hypopituitarism 30.6 LEP INS HSD11B1
37 familial partial lipodystrophy 30.6 PPARG LEP INS ADIPOQ
38 lipid metabolism disorder 30.6 SERPINE1 PPARG MIR33A MIR122 LEP INS
39 thyroid gland disease 30.5 PPARG LEP INS
40 coronary heart disease 1 30.5 SERPINE1 INS ADIPOQ
41 polycystic ovary syndrome 30.5 PPARG LEP INS GHRL ADIPOQ
42 type 1 diabetes mellitus 30.5 MEG3 LEP INS ADIPOQ
43 familial hypercholesterolemia 30.4 SERPINE1 NOS3 LEP INS ADIPOQ
44 hyperuricemia 30.4 PPARG LEP INS
45 glucose metabolism disease 30.4 SERPINE1 PPARG NOS3 LEP INS GHRL
46 lipodystrophy, familial partial, type 2 30.4 PPARG LEP INS ADIPOQ
47 hernia, hiatus 30.4 GHRL ADIPOQ
48 bulimia nervosa 30.3 LEP INS GHRL
49 disease of mental health 30.3 SLC2A1 SERPINE1 PPARG NOS3 MIR122 LEP
50 angina pectoris 30.3 NOS3 INS ADIPOQ

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1
Sources

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

About this section

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

31
# Description HPO Frequency HPO Source Accession
1 hypertension 31 HP:0000822
2 abdominal obesity 31 HP:0012743

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM®:

605552 (Updated 20-May-2021)

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.31 ADIPOQ GHRL HSD11B1 INS LEP MTM1
2 cardiovascular system MP:0005385 10.26 ADIPOQ HSD11B1 INS KMT2B LEP MTM1
3 growth/size/body region MP:0005378 10.22 ADIPOQ HSD11B1 INS KMT2B LEP MTM1
4 adipose tissue MP:0005375 10.21 ADIPOQ GHRL HSD11B1 INS KMT2B LEP
5 cellular MP:0005384 10.2 ADIPOQ HSD11B1 INS KMT2B LEP MTM1
6 homeostasis/metabolism MP:0005376 10.18 ADIPOQ GHRL HSD11B1 INS KMT2B LEP
7 endocrine/exocrine gland MP:0005379 10.13 ADIPOQ GHRL HSD11B1 INS KMT2B LEP
8 integument MP:0010771 9.97 ADIPOQ HSD11B1 INS LEP NAGLU PPARG
9 liver/biliary system MP:0005370 9.96 ADIPOQ HSD11B1 INS KMT2B LEP MTM1
10 muscle MP:0005369 9.76 ADIPOQ HSD11B1 INS LEP MTM1 NOS3
11 nervous system MP:0003631 9.7 ADIPOQ HSD11B1 INS KMT2B LEP NAGLU
12 renal/urinary system MP:0005367 9.23 ADIPOQ INS LEP NAGLU NOS3 PPARG
Sources

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

About this section

PubMed Health treatment related to Abdominal Obesity-Metabolic Syndrome 1: 62

Healthy lifestyle changes are the first line of treatment for metabolic syndrome . Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking . If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure , high triglycerides , low HDL cholesterol , and high blood sugar . Blood -thinning medicines, such as aspirin , also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome .

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 579)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
2
Lactitol Approved, Investigational Phase 4 585-86-4 157355
3
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Testosterone Approved, Investigational Phase 4 58-22-0 6013
12
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
13
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Ezetimibe Approved Phase 4 163222-33-1 150311
16
Nifedipine Approved Phase 4 21829-25-4 4485
17
Galantamine Approved Phase 4 357-70-0 9651
18
Ramipril Approved Phase 4 87333-19-5 5362129
19
Titanium dioxide Approved Phase 4 13463-67-7
20
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
21
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
22
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
23
Doxazosin Approved Phase 4 74191-85-8 3157
24
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
25
Sodium citrate Approved, Investigational Phase 4 68-04-2
26
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
27
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
28
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
29
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
30
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
31
Atenolol Approved Phase 4 29122-68-7 2249
32
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
33
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
34
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
35
Trandolapril Approved Phase 4 87679-37-6 5484727
36
Verapamil Approved Phase 4 52-53-9 2520
37
Infliximab Approved Phase 4 170277-31-3
38
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
39
Bisoprolol Approved Phase 4 66722-44-9 2405
40
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
41
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
42
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
43
Polyestradiol phosphate Approved Phase 4 28014-46-2
44
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
45
Captopril Approved Phase 4 62571-86-2 44093
46
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
47
Chlorthalidone Approved Phase 4 77-36-1 2732
48
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
49
Febuxostat Approved Phase 4 144060-53-7 134018
50
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807

Interventional clinical trials:

(show top 50) (show all 1630)
# Name Status NCT ID Phase Drugs
1 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
2 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
3 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
4 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
5 Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
6 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
7 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
8 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
9 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
10 the Long-term Effects of High-doSe pitavaStatin on Diabetogenicity in Comparison With Atorvastatin in Patients With Metabolic Syndrome (LESS-DM) Randomized Clinical Trial Unknown status NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
11 The Effect of Probiotics on Obesity. Metabolic Endotoxemia and Inflammation Unknown status NCT03883685 Phase 4
12 Comparison of the Efficacy and Safety of Berberine and Metformin for Schizophrenia Patients With Metabolic Syndrome Unknown status NCT03708549 Phase 4 Berberine;Metformin
13 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
14 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
15 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
16 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
17 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
18 A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure Completed NCT00894868 Phase 4 vildagliptin;placebo of vildagliptin
19 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
20 PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
21 A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
22 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
23 Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine Completed NCT01401491 Phase 4 clozapine plus fluvoxamine;clozapine plus placebo
24 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
25 Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT) Completed NCT00815659 Phase 4 rosuvastatin
26 Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism Completed NCT00287820 Phase 4 Olanzapine;olanzapine;risperidone
27 Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome Completed NCT00444717 Phase 4 pitavastatin
28 A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome Completed NCT00385658 Phase 4 Fluvastatin extended release, fenofibrate;Fixed combination simvastatin/ezetimibe
29 A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS] Completed NCT00325936 Phase 4 Cilnidipine
30 A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome Completed NCT00241150 Phase 4 VALSARTAN
31 Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
32 The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
33 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
34 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
35 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
36 Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome Completed NCT01819220 Phase 4 amlodipine/valsartan;hydrochlorothiazide/telmisartan
37 Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
38 Effect of Caduet and TLC Intervention on Metabolic Parameters Completed NCT03504735 Phase 4 Caduet Pill;Placebo
39 Effect of Aged Garlic Extract on Atherosclerosis Completed NCT01534910 Phase 4 aged garlic extract;placebo
40 Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities Completed NCT02751307 Phase 4 metformin 500 mg;clozapine 100 mg
41 The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
42 A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
43 Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance Completed NCT00835120 Phase 4 Pioglitazone
44 Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome Completed NCT01625442 Phase 4 Saffron tablet;Barberry tablet;Placebo
45 Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome Completed NCT00487734 Phase 4 Placebo for testosterone gel
46 Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome Completed NCT00666848 Phase 4 Placebo;Enalapril 5mg;Enalapril 10mg;Sitagliptin
47 Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome Completed NCT00775671 Phase 4 placebo;Nebivolol;Metoprolol
48 Mechanisms Underlying Metabolic Syndrome in Obesity Completed NCT00579813 Phase 4 Pioglitazone
49 The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome Completed NCT00819403 Phase 4 simvastatin;ezetimibe/simvastatin
50 The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Sources

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

About this section

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 29
Sources

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

About this section

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

40
Heart, Liver, Endothelial, Bone, Ovary, Prostate, Breast
Sources

Publications for Abdominal Obesity-Metabolic Syndrome 1

About this section

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 964)
# Title Authors PMID Year
1
Prospective analysis of the insulin-resistance syndrome (syndrome X). 57 54
1587398 1992
2
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
3
Screening of 336 single-nucleotide polymorphisms in 85 obesity-related genes revealed McKusick-Kaufman syndrome gene variants are associated with metabolic syndrome. 57
19247371 2009
4
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. 57
18587407 2008
5
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. 57
18305138 2008
6
Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. 57
17273170 2007
7
Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. 57
16391564 2006
8
The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. 57
16446448 2006
9
A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. 57
16721486 2006
10
Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. 6
16204371 2005
11
Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study. 57
16046320 2005
12
Retinoid x receptor heterodimers in the metabolic syndrome. 57
16093469 2005
13
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 57
16043803 2005
14
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. 57
15919835 2005
15
Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. 57
15562396 2004
16
Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. 57
15309680 2004
17
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. 57
14557872 2003
18
Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. 57
12970275 2003
19
Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. 57
12917706 2003
20
Association of low interleukin-10 levels with the metabolic syndrome in obese women. 57
12629085 2003
21
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. 57
12588201 2003
22
A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. 6
12161552 2002
23
Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. 6
12050239 2002
24
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. 57
11790215 2002
25
A transgenic model of visceral obesity and the metabolic syndrome. 57
11739957 2001
26
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 57
11734540 2001
27
Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. 6
11502844 2001
28
Cardiovascular morbidity and mortality associated with the metabolic syndrome. 57
11315831 2001
29
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. 57
11121050 2000
30
Metabolic implications of body fat distribution. 57
1773700 1991
31
Banting lecture 1988. Role of insulin resistance in human disease. 57
3056758 1988
32
MiR-33 contributes to the regulation of cholesterol homeostasis. 47
20466885 2010
33
Altered body composition in preterm infants at hospital discharge. 54 61
19594474 2009
34
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. 61 54
18049445 2007
35
[The metabolic syndrome X or insulin resistance syndrome]. 54 61
17304724 2007
36
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. 61 54
16941796 2006
37
Expression analysis of genes involved in fat assimilation in human monocytes. 61 54
16801219 2006
38
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 61 54
17119268 2006
39
Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. 61 54
16641887 2006
40
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. 47
16459310 2006
41
Pathophysiology of metabolic syndrome X and its links to the perinatal period. 54 61
15925303 2005
42
The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. 61 54
15505005 2004
43
Infants of diabetic mothers. 61 54
15157588 2004
44
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? 61 54
15025845 2004
45
Metabolic syndrome X: an inflammatory condition? 54 61
14972097 2004
46
Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. 54 61
15104027 2004
47
Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. 54 61
15078145 2004
48
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. 61 54
14574352 2003
49
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. 54 61
12946657 2003
50
[Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow]. 54 61
12967888 2003
Sources

Variations for Abdominal Obesity-Metabolic Syndrome 1

About this section

ClinVar genetic disease variations for Abdominal Obesity-Metabolic Syndrome 1:

6 (show all 15)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LOC110973015 , NOS3 NM_000603.5(NOS3):c.-51-762C>T SNV protective 517660 rs2070744 GRCh37: 7:150690079-150690079
GRCh38: 7:150992991-150992991
2 MTM1 NC_000023.11:g.150583230_150648535del Deletion Pathogenic 812933 GRCh37: X:149751687-149817005
GRCh38:
3 TYR NM_000372.5(TYR):c.1A>G (p.Met1Val) SNV Pathogenic 3807 rs28940881 GRCh37: 11:88911122-88911122
GRCh38: 11:89177954-89177954
4 KMT2B NM_014727.3(KMT2B):c.3143_3149del (p.Gly1048fs) Deletion Pathogenic 813003 rs1599677213 GRCh37: 19:36214713-36214719
GRCh38: 19:35723812-35723818
5 NAGLU NM_000263.4(NAGLU):c.419A>G (p.Tyr140Cys) SNV Pathogenic 371634 rs753520553 GRCh37: 17:40689451-40689451
GRCh38: 17:42537433-42537433
6 NAGLU NM_000263.4(NAGLU):c.507_516del (p.Ser169fs) Deletion Pathogenic 1564 rs483352897 GRCh37: 17:40689535-40689544
GRCh38: 17:42537517-42537526
7 NOS3 NM_000603.5(NOS3):c.894T>G (p.Asp298Glu) SNV risk factor 496809 rs1799983 GRCh37: 7:150696111-150696111
GRCh38: 7:150999023-150999023
8 SLC2A1 NM_006516.3(SLC2A1):c.859A>C (p.Ile287Leu) SNV Likely pathogenic 625201 rs1431778557 GRCh37: 1:43395272-43395272
GRCh38: 1:42929601-42929601
9 GHRL , GHRLOS NM_016362.5(GHRL):c.214C>A (p.Leu72Met) SNV risk factor 5062 rs696217 GRCh37: 3:10331457-10331457
GRCh38: 3:10289773-10289773
10 TYR NM_000372.5(TYR):c.325G>A (p.Gly109Arg) SNV Likely pathogenic 99562 rs61753253 GRCh37: 11:88911446-88911446
GRCh38: 11:89178278-89178278
11 PTS NM_000317.2(PTS):c.(?_-1)_(*1_?)del Deletion Likely pathogenic 375224 GRCh37:
GRCh38:
12 TYR NM_000372.5(TYR):c.1205G>A (p.Arg402Gln) SNV Likely pathogenic 3779 rs1126809 GRCh37: 11:89017961-89017961
GRCh38: 11:89284793-89284793
13 GHRL , GHRLOS NM_016362.5(GHRL):c.152G>A (p.Arg51Gln) SNV risk factor 5061 rs34911341 GRCh37: 3:10331519-10331519
GRCh38: 3:10289835-10289835
14 LMNA NM_170707.4(LMNA):c.1892G>A (p.Gly631Asp) SNV Uncertain significance 66873 rs267607648 GRCh37: 1:156108472-156108472
GRCh38: 1:156138681-156138681
15 NRL NM_006177.5(NRL):c.448_466dup (p.Glu156fs) Duplication Uncertain significance 523490 rs1555339028 GRCh37: 14:24550692-24550693
GRCh38: 14:24081483-24081484

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome
Sources

Expression for Abdominal Obesity-Metabolic Syndrome 1

About this section
Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.
Sources

Pathways for Abdominal Obesity-Metabolic Syndrome 1

About this section

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Glucose / Energy Metabolism 4
12.34 TYR SLC2A1 PPARG INS ADIPOQ
2
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.29 PPARG NOS3 LEP INS ADIPOQ
3
AMPK Enzyme Complex Pathway 63
Show member pathways
 12.01 SLC2A1 NOS3 LEP INS
4
Insulin resistance 36
Show member pathways
 11.77 SLC2A1 NOS3 INS
5
HIF-1 signaling pathway 36
11.74 SLC2A1 SERPINE1 NOS3 INS
6
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.6 PPARG LEP INS ADIPOQ
7
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.56 PPARG MIR33A INS
8
Adipocytokine signaling pathway 36
11.53 SLC2A1 LEP ADIPOQ
9
HIF-1-alpha transcription factor network 1
11.48 SLC2A1 SERPINE1 LEP
10
Adipogenesis 1
11.47 SERPINE1 PPARG LEP INS ADIPOQ
12
Differentiation of white and brown adipocyte 1
10.94 PPARG LEP ADIPOQ
13
Transcription factor regulation in adipogenesis 1
10.78 PPARG LEP ADIPOQ
14
Cori Cycle 1
10.74 SLC2A1 INS
15
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.63 LEP INS GHRL
Sources

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

About this section

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cellular response to insulin stimulus GO:0032869 9.69 PPARG LEP ADIPOQ
2 positive regulation of cold-induced thermogenesis GO:0120162 9.67 LEP GHRL ADIPOQ
3 circadian rhythm GO:0007623 9.63 SERPINE1 LEP ADIPOQ
4 response to nutrient GO:0007584 9.61 PPARG LEP ADIPOQ
5 response to nutrient levels GO:0031667 9.58 LEP GHRL ADIPOQ
6 negative regulation of gluconeogenesis GO:0045721 9.54 INS ADIPOQ
7 fatty acid oxidation GO:0019395 9.52 PPARG ADIPOQ
8 regulation of blood pressure GO:0008217 9.5 PPARG NOS3 LEP
9 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.48 PPARG ADIPOQ
10 adult feeding behavior GO:0008343 9.37 LEP GHRL
11 negative regulation of acute inflammatory response GO:0002674 9.26 PPARG INS
12 glucose metabolic process GO:0006006 9.26 LEP INS GHRL ADIPOQ
13 positive regulation of fatty acid metabolic process GO:0045923 9.16 PPARG ADIPOQ
14 glucose homeostasis GO:0042593 9.02 PPARG MIR33A LEP INS ADIPOQ

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 LEP INS GHRL ADIPOQ
Sources

Sources for Abdominal Obesity-Metabolic Syndrome 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....